BRCA2 and breast carcinoma: RTx-303 was administeredat 60 mg/kg (po, bid) in combination with 0.12 mg/kg (po, qd) talazoparibfor 42 days in female BALB/c mice inoculated with different BRCA2 mutant breast cancer PDX model (BR-05–0568).The combination treatment resulted in complete elimination of alltumors (Figure C,left).